Hypertension Management by Pharmacist Interventions

By Danélia Botes

November 10, 2023

The Rising Challenge of Hypertension

Hypertension management, a significant risk factor for cardiovascular and kidney diseases, is a leading cause of preventable death and disability globally. With more than 100 million people affected in the US alone, the healthcare costs associated with hypertension surpassed $130 billion between 2003 and 2014. Despite the availability of affordable medications and lifestyle interventions, blood pressure control rates continue to decline.

Pharmacist Interventions: A New Approach to Hypertension Management

Recent research suggests an innovative solution: pharmacist-led interventions. Pharmacists, who often see patients more frequently than physicians, are well-positioned to screen and manage hypertension. Numerous clinical trials have demonstrated improved hypertension outcomes through pharmacist-led case-finding and prescribing interventions.


A cost-effectiveness analysis of implementing pharmacist prescribing for hypertension management in the US has yielded promising results. The pharmacist intervention was associated with 2100 fewer cases of cardiovascular disease and 8 fewer cases of kidney disease per 10,000 patients. Furthermore, it resulted in overall cost savings of $10,162 per person.

Reference url

Recent Posts

neoadjuvant chemotherapy ovarian cancer
       

Neoadjuvant Chemotherapy: Transforming Treatment for Advanced Ovarian Cancer

🚀 Neoadjuvant chemotherapy is reshaping the landscape of advanced epithelial ovarian cancer treatment!

This method not only improves disease management but marks a significant shift from traditional approaches. With ongoing studies highlighting its efficacy and the importance of supportive care, it’s crucial to address both patient and caregiver needs.

Explore the latest insights on treatment patterns, survival outcomes, and the need for greater patient involvement in decisions that affect their health.

#SyenzaNews #OvarianCancer #HealthcareInnovation

rifaximin antibiotic resistance
     

Rifaximin Use Linked to Daptomycin Resistance: Implications for Antibiotic Stewardship

🚨 Important findings alert!

A recent article in Nature unveils critical insights into the unintended consequences of rifaximin use, particularly its role in fostering resistance to the crucial antibiotic daptomycin. This research highlights the need for careful antibiotic stewardship to combat the rise of antibiotic-resistant infections. 🌍

Jump into these results and their implications for public health!

#SyenzaNews #AntibioticResistance #PublicHealth

Equitable AI Healthcare
      

Global Equitable AI Healthcare: Grant Initiatives and Innovations

🌍 Exciting news from the South African Medical Research Council!

The “Grand Challenges: Catalysing Equitable AI Use for Improved Global Health” initiative is empowering over 50 researchers to address pressing healthcare issues. With a focus on equitable AI, this program aims to ensure accessible healthcare solutions for underserved populations worldwide. Discover how local innovation and global collaboration can transform health outcomes!

#SyenzaNews #GlobalHealth #AIforGood

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.